Results 271 to 280 of about 219,440 (288)
Some of the next articles are maybe not open access.
Blood, 2008
In this issue of Blood , Ellis and colleagues report on the interaction of SNPs in the p53 tumor suppressor pathway and in the MDM2 309 locus in susceptibility to therapy-related AML. Genetic variants are associated with disease susceptibility.[1][1],[2][2] Of the genetic variants, single-
openaire +3 more sources
In this issue of Blood , Ellis and colleagues report on the interaction of SNPs in the p53 tumor suppressor pathway and in the MDM2 309 locus in susceptibility to therapy-related AML. Genetic variants are associated with disease susceptibility.[1][1],[2][2] Of the genetic variants, single-
openaire +3 more sources
ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?
Clinical Lymphoma Myeloma and Leukemia, 2015Background: Additional sex combs like transcription factor 1 (ASXL1) is a member of the polycomb group protein. ASXL1 mutation has been implicated in myeloid malignancy transformation. It is hypothesized that mutated ASXL1 leads to the loss of polycomb repressive complex 2 (PRC2) mediated gene repression and subsequent transforming events.
Elizabeth O. Hexner +11 more
openaire +2 more sources
Cytotherapy, 2002
BMT is a potentially curative treatment for patients with most forms of myeloid leukemia, such as AML and CML. Cure rates are 50‐80% for patients with leukemia given an allogeneic BMT from a related donor, such as a brother or sister. The pre-transplant conditioning regimen reduces the number of leukemia cells in the recipient, however, it is the donor’
openaire +3 more sources
BMT is a potentially curative treatment for patients with most forms of myeloid leukemia, such as AML and CML. Cure rates are 50‐80% for patients with leukemia given an allogeneic BMT from a related donor, such as a brother or sister. The pre-transplant conditioning regimen reduces the number of leukemia cells in the recipient, however, it is the donor’
openaire +3 more sources
1994
Although the results of AML treatment have been considerably improved during the last years, it is almost entirely concerned the patients less than 60 years old. The age of the patient still remains one of the important facts of unfavourable prognosis as regards achievement of remission and survival [1-7]. The mean complete remission rate is lower than
S. M. Kulikov +3 more
openaire +2 more sources
Although the results of AML treatment have been considerably improved during the last years, it is almost entirely concerned the patients less than 60 years old. The age of the patient still remains one of the important facts of unfavourable prognosis as regards achievement of remission and survival [1-7]. The mean complete remission rate is lower than
S. M. Kulikov +3 more
openaire +2 more sources
2001
It is commonly accepted that elderly patients with AML have much worse outcomes than younger patients due to increased risk of both early death and resistant disease. Beyond this truism several points should be addressed. First, because other variables (e.g. performance status, organ function) besides age predict these outcomes, it may not be advisable
M. Beran +4 more
openaire +2 more sources
It is commonly accepted that elderly patients with AML have much worse outcomes than younger patients due to increased risk of both early death and resistant disease. Beyond this truism several points should be addressed. First, because other variables (e.g. performance status, organ function) besides age predict these outcomes, it may not be advisable
M. Beran +4 more
openaire +2 more sources
2007
As with any disease, there are three general options for treatment of AML: supportive care only, standard therapy, and investigational therapy. Although, as discussed below, there are instances where the first option is preferable, the natural history of AML typically mitigates against it [1].
openaire +2 more sources
As with any disease, there are three general options for treatment of AML: supportive care only, standard therapy, and investigational therapy. Although, as discussed below, there are instances where the first option is preferable, the natural history of AML typically mitigates against it [1].
openaire +2 more sources
Nature Reviews Cancer, 2018
Assi et al. have generated multi-omics data on leukaemic blasts from acute myeloid leukaemia (AML) patients with defined genetic alterations. These data provide a comprehensive overview of the specific transcriptional and signalling networks in certain AML subtypes.
openaire +3 more sources
Assi et al. have generated multi-omics data on leukaemic blasts from acute myeloid leukaemia (AML) patients with defined genetic alterations. These data provide a comprehensive overview of the specific transcriptional and signalling networks in certain AML subtypes.
openaire +3 more sources
Blood, 2009
Published results of clinical trials in AML are only applicable to a select group of patients and are not representative of the entire population.
openaire +3 more sources
Published results of clinical trials in AML are only applicable to a select group of patients and are not representative of the entire population.
openaire +3 more sources
IEEE Transactions on Automatic Control, 1979
In this work it is shown that provided a certain positive real condition is satisfied, the AML recursion for the parameters of a scalar ARMAX time series model converges with probability one without the need of monitoring. Previous proofs of convergence had effectively required that the recursion be monitored.
openaire +2 more sources
In this work it is shown that provided a certain positive real condition is satisfied, the AML recursion for the parameters of a scalar ARMAX time series model converges with probability one without the need of monitoring. Previous proofs of convergence had effectively required that the recursion be monitored.
openaire +2 more sources
2009
Several, acquired, non-random chromosomal deletions have been characterized in acute myelogenous leukemia (AML). While the deletion limits vary among patients, there are consistent regions of overlap among the deleted segments between patients. Furthermore, chromosomal deletions are achieved frequently by unbalanced translocations between two and more ...
openaire +2 more sources
Several, acquired, non-random chromosomal deletions have been characterized in acute myelogenous leukemia (AML). While the deletion limits vary among patients, there are consistent regions of overlap among the deleted segments between patients. Furthermore, chromosomal deletions are achieved frequently by unbalanced translocations between two and more ...
openaire +2 more sources